Mural to Host 1x1 Investor Meetings at 14th Annual East Coast IDEAS Conference

Mural Oncology plc, a clinical-stage immuno-oncology company listed on Nasdaq under the ticker MURA, has announced that its CEO, Dr. Caroline Loew, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. The presentation will be available via webcast on the company's investor relations website.

The IDEAS Investor Conferences aim to create independent regional platforms where promising companies can showcase their investment potential to a select group of investment professionals. Distinct from traditional bank-sponsored events, these conferences are organized by investors for the benefit of regional investment communities. The conferences are supported by sponsors managing assets totaling over $200 billion, including prominent firms such as Allianz Global Investors, Ariel Investments, BMO Global Asset Management, and William Harris Investors, among others. These events are produced annually by Three Part Advisors, LLC.

Mural Oncology is dedicated to developing innovative cytokine-based immunotherapies to treat cancer. Utilizing a proprietary protein engineering platform, the company aims to advance the field of cytokine biology and immune modulation to create therapies that offer significant clinical benefits for cancer patients. Mural Oncology's flagship candidate, nemvaleukin, is currently undergoing late-stage clinical trials for mucosal melanoma and platinum-resistant ovarian cancer. The company operates out of Dublin, Ireland, with primary facilities located in Waltham, Massachusetts.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!